全新药物设计方法与常用软件及其在抗癌药物设计中的应用

殷丽; 陈临溪

doi:10.3969/j.issn.1006-0111.2014.01.003

全新药物设计方法与常用软件及其在抗癌药物设计中的应用

doi: 10.3969/j.issn.1006-0111.2014.01.003

殷丽,
陈临溪

南华大学药物药理研究所, 湖南衡阳 421001

基金项目: 国家自然科学基金(81270420);教育部留学归国人员科研启动基金(20091590);湖南省高校创新平台开放基金(10K051);湖南省自然科学基金省市联合(衡阳)基金重点项目(12JJ8013);湖南省十二五重点学科资助.

Applications of the common software and methods of denovo drug design in the antitumor drug design

YIN Li,
CHEN Linxi

Institute of Pharmacy and Pharmacology, University of South China, Hunan Hengyang 421001, China

摘要: 计算机辅助药物设计已普遍应用于药物研发过程,大大加快了药物开发的速度。特别是全新药物设计方法可以用于识别作用于特异性靶点的全新配体结构。全新药物设计常用软件有LUDI,LigBuilder,LeapFrog,SPROUT和SYNOPSIS等,常用方法有片段连接、片段生长、侧链替换和骨架跃迁等。全新药物设计方法在一些抗癌化合物,如纺锤体驱动蛋白抑制剂、血管内皮生长因子抑制剂、亲环蛋白A抑制剂和BRAF抑制剂等的发现方面,已经发挥了重要作用。综述全新药物设计方法与常用软件,并举例讨论其在新型抗癌药物领域中的应用。
- 全新药物设计 /
- 抗癌药 /
- LUDI /
- LigBuilder /
- LeapFrog
Abstract: Computer aided drug design had become part of the drug discovery process, greatly improved the speed of drug development compared with traditional drug finding methods. In particular, the de novo drug design method could be used to identify ligands with novel structure for a special target. Through computer simulation, researchers could find new ideas about how to change a compound to improve the drug properties or how to assemble some fragments to generate candidates which be drug-like, synthetically accessible and high affinity for a target. The common software of de novo design included LUDI, MCSS, LigBuilder, SPROUT, SYNOPSIS, BREED, LeapFrog and RACHEL, etc. The methods were fragments link and grow, side chain replacement, parent molecule evolve, template, scaffold hopping and so on. Discovery and development of cancer drugs had been revolutionized over the last decade. De novo drug design methods had already played a significant role in the discovery of some anticancer compounds such as kinesin spindle protein inhibitors, vascular endothelial growth factor inhibitors, cyclophilin A inhibitors, cell division cycle protein CDC25 inhibitors and BRAF inhibitors. The common software and methods of de novo drug design were summarized in this review and their applications in antitumor drug design were discussed.
- de novo drug design /
- antitumor drug /
- LUDI /
- LigBuilder /
- LeapFrog

[1]	Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs:successes, challenges and opportunities[J]. Mol Oncol, 2012, 6 (2):155-176.
[2]	Kalyaanamoorthy S, Phoebe Chen Y-P. Structure-based drug design to augment hit discovery[J]. Drug Discov Today, 2011, 16(17-18):831-839.
[3]	Kutchukian PS, Shakhnovich EI. De novo design:balancing novelty and confined chemical space[J]. Expert Opin Drug Discov, 2010. 5(8), 789-812.
[4]	Park H, Jeong Y, Hong S. Structure-based de novo design and biochemical evaluation of novel BRAF kinase inhibitors[J]. Bioorg Med Chem Lett, 2012, 22(2):1027-1030.
[5]	Schneider G, Fechner U. Computer-based de novo design of drug-like molecules[J]. Nat Rev Drug Discov 2005, 4 (8):694-663.
[6]	Lipinski,C, Hopkins A. Navigating chemical space for biology and medicine[J]. Nature, 2004,432(7019):855-861.
[7]	Platania CB, Salomone S, Leggio GM, et al. Homology modeling of dopamine d(2) and d(3) receptors:molecular dynamics refinement and docking evaluation[J]. PloS One, 2012, 7 (9):44316.
[8]	Keseru GM, Makara GM. Hit discovery and hit-to-lead approaches[J]. Drug Discov Today, 2006, 11(15-16), 741-748.
[9]	Bohm HJ. The computer program LUDI:a new method for de novo design of enzyme inhibitors[J]. J Comput Aided Mol Des, 1992, 6 (1):61-78.
[10]	Wang RX, Gao Y, Lai LH. LigBuilder:a multi-purpose progrom for structure-based drug design[J]. J Mol Model, 2000, 6 (7-8); 498-516.
[11]	Wang RX, Liu L, Lai LH, et al. SCORE:A new empirical method for estimating the binding affinity of a protein-ligand complex[J]. J Mol Model, 1998, 4 (12):370-394.
[12]	Yuan,YX, Pei JF, Lai LH. LigBuilder 2:a practical de novo drug design approach[J]. J Chem Inform Model, 2011, 51 (5):1083-1091.
[13]	Cramer RD. Design and preliminary results of LeapFrog, a second generation de novo drug discovery tool[J]. J Mol Graphics, 1993, 11(4); 271-272.
[14]	Ambure PS, Gangwal RP, Sanganwar AT. 3D-QSAR and molecular docking analysis of biphenyl amide derivatives as p38α mitogen-activated protein kinase inhibitors[J]. Mol Divers, 2012,16(2):377-388.
[15]	Makhija MT, Kasliwal RT, Kulkarni VM, et al. De novo design and synthesis of HIV-1 integrase inhibitors[J]. Bioorg Med Chem, 2004, 12(9):2317-2333.
[16]	Schinerider G, Neidhart W, Giller T, et al. Scaffold-Hopping by topological search:a contribution to virtual screening[J]. Angewandte Chemie (International Ed. in English), Angew Chem Int Ed Engl, 1999, 38(19):2894-2896.
[17]	Schneider G. De novo design-hopping against hope[EB/OL]. Drug Discovery Today:Technologies.(2012-06-20)[2013-01-02].
[18]	Wolber G. 3D pharmacophore elucidation and virtual screening[J]. Drug Discov Today, 2010, 7(4):203-204.
[19]	Lauri G, Bartlett PA. CAVEAT:a program to facilitate the design of organic molecules[J]. J Comput Aided Mol Des, 1994, 8(1):51-66.
[20]	Beno BR, Langley DR. MORPH:a new tool for ligand design[J]. J Chem Inform Model, 2010, 50(6):1159-1164.
[21]	Maass P, Schulz-Gasch T, Stahl M, et al. Recore:a fast and versatile method for scaffold hopping based on small molecule crystal structure conformations[J]. J Chem Inform Model, 2007,47(2):390-399.
[22]	Gillet VJ, Newell W, Mata P, et al. SPROUT:recent developments in the de novo design of molecules[J]. J Chem Inform Comput Sci, 1994, 34:207-217.
[23]	Vinkers HM, de Jonge MR, Daeyaert FF, et al. SYNOPSIS:SYNthesize and optimize system in silico[J]. J Med Chem, 2003, 46:2765-2773.
[24]	Pierce AC, Rao G, Bemis GW, et al. BREED generating novel inhibitors through hybridization of known ligands. Aplication to CDK2, p38and HIV protease[J]. J Med Chem, 2004, 47:2768-2775.
[25]	Marra E, Palombo F, Ciliberto G, et al. Intratumoral electro-transfer of small interfering RNA against kinesin spindle protein (KSP) slows down tumor progression[J]. J Cell Physiol, 2013,228(1),58-64.
[26]	Jiang,C, Yang L, Wu WT, et al. De novo design, synthesis and biological evaluation of 1,4-dihydroquinolin-4-ones and 1,2,3,4-tetrahydroquinazolin-4-ones as potent kinesin spindle protein (KSP) inhibitors[J]. Bioorg Med Chem, 2011,19 (18):5612-5627.
[27]	Kim LA, D'Amore PA. A brief history of anti-VEGF for the treatment of ocular angiogenesis[J]. Am J Pathol, 2012, 181(2):376-379.
[28]	Uno M, Ban HS, Nabeyama W, et al. De novo design and synthesis of N-benzylanilines as new candidates for VEGFR tyrosine kinase inhibitors[J]. Org Biomol Chem, 2008, 6 (6):979-981.
[29]	Albert H, Santos S, Battaqlia E, et al. Differential expression of CDC25 phosphatases splice variants in human breast cancer cells[J]. Clin Chem Lab Med, 2011, 49(10):1707-1714.
[30]	Park H, Bahn YJ, Ryu SE, Structure-based de novo design and biochemical evaluation of novel Cdc25 phosphatase inhibitors[J]. Bioorg Med Chem Lett, 2009, 19(15):4330-4334.
[31]	Zhou DJ, Mei Q, Li JT, et al, Cyclophilin A and viral infections[J]. Bioch Biophys Res Comm, 2012,424(4), 647-650.
[32]	Choi KJ, Piao YJ, Lim MJ, et al. Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia-and cisplatin-induced cell death[J]. Cancer Res, 2007, 67(8):3654-3662.
[33]	Ni SS, Yuan YX, Huang J, et al. Discovering potent small molecule inhibitors of cyclophilin A using de novo drug design approach[J]. J Med Chem, 2009, 52(17):5295-5298.
[34]	Wong C, Chen S. The development,application and limitations of breast cancer cell lines to study tamoxifen and aromataes inhibitor resistance[J]. J Steroid Biochem Mol Biol, 2012, 131(3-5):83-92.
[35]	Gueto C, Torres J, Vivas-Reyes R. CoMFA, LeapFrog and blind docking studies on sulfonanilide derivatives acting as selective aromatase expression regulators[J]. Eur J Med Chem, 2009, 44(9):3445-3451.
[36]	Su B, Diaz-Cruz ES, Landini S, et al. Novel sulfonanilide analoguew suppress aromataes expression and activity in breast cancer cells independent of COX-2 inhibiton[J]. J Med Chem, 2006, 49(4):1413-1419.
[37]	Davies H, Bignell GR, Cox C, et al. Mutations of the B-raf gene in human cancer[J]. Nature, 2002, 417(6892), 949-954.
[38]	Gopalsamy A, Shi M, Hu Y, et al. B-raf kinase inhibitors:hit enrichment through scaffold hopping[J]. Bioorg Med Chem Lett, 2010, 20(8):2431-2434.

[1]	杨彬, 李鑫, 韦平, 褚征. 门诊药房发药辅助系统的设计与应用 . 药学实践与服务, 2023, 41(6): 389-392. doi: 10.12206/j.issn.2097-2024.202106003
[2]	周许薇, 谭蔚锋, 解方园, 辛宝, 陈俊. 双氢青蒿素抗癌药理作用机制的研究进展 . 药学实践与服务, 2019, 37(3): 206-211,278. doi: 10.3969/j.issn.1006-0111.2019.03.003
[3]	贾静, 李悦悦, 朱臻宇, 柴逸峰, 张国庆. 3种常用抗癌药物对人肝癌细胞HepG2抑制作用的研究 . 药学实践与服务, 2009, 27(5): 323-333,361.
[4]	亓云鹏, 范国荣, 柴逸峰, 张东春, 陆峰. “制订新药质量标准”设计性实验的教学体会 . 药学实践与服务, 2007, (3): 186-187.
[5]	江力宣, 闫海英, 阳盛洪, 邱旭民. 药代动力学研究在新药研发中的应用 . 药学实践与服务, 2006, (5): 260-263,288.
[6]	张国庆, 赵亮, 李捷玮, 王彬, 龚纯贵. 中心摆药室单剂量调配制的设计研究 . 药学实践与服务, 2005, (2): 78-80.
[7]	王文森, 路绪文, 孙洁. 加强药事管理委员会对新药引进的监督管理 . 药学实践与服务, 2001, (2): 122-122,95.
[8]	任宏斌, 魏红. 金属配合物抗癌药物研究 . 药学实践与服务, 2001, (2): 117-119.
[9]	王昊, 丁如贤, 秦路平. 抗癌植物—红豆杉(摘要) . 药学实践与服务, 2000, (5): 348-348.
[10]	李蔚. 非抗癌药物的抗癌作用 . 药学实践与服务, 1999, (3): 139-139.
[11]	刘洪涛, 孙福红. 有机硒的抗癌研究 . 药学实践与服务, 1994, (2): 8-11.
[12]	王茂义. 高效液相色谱检测血中抗癌药浓度 . 药学实践与服务, 1993, (3): 216-217.
[13]	哈明凤, 徐咏梅, 朱全刚, 张紫洞. 新药物和新剂型 . 药学实践与服务, 1992, (1): 27-28.
[14]	孟照华, 刘元秀, 栾发云, 李泽普, 李德本, 侯爱中. 速效止痛抗癌丸(膏) . 药学实践与服务, 1989, (4): 28-29.
[15]	刘锡钧, 齐荔红, 许景峰. 新型抗癌药胺苯吖啶的临床应用 . 药学实践与服务, 1989, (4): 29-31.
[16]	RiechK. 抗癌药物对人体的致癌性 . 药学实践与服务, 1987, (1): 23-29.
[17]	贾丹兵, 张紫洞. 新型液体药物缓释剂型设计 . 药学实践与服务, 1986, (3): 58-58.
[18]	HeinrichKoch. 碳铂:新的铂类抗癌药 . 药学实践与服务, 1986, (4): 9-10.
[19]	鱼爱和, 张紫洞. 巯乙磺酸钠(Mesna)—抗癌药引起尿路毒性的解毒剂 . 药学实践与服务, 1985, (3): 11-12.
[20]	廖名龙. 抗癌药的新用途 . 药学实践与服务, 1985, (1): 18-18.

点击查看大图

计量

文章访问数: 2432
HTML全文浏览量: 168
PDF下载量: 506
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

全新药物设计方法与常用软件及其在抗癌药物设计中的应用

doi: 10.3969/j.issn.1006-0111.2014.01.003

Applications of the common software and methods of denovo drug design in the antitumor drug design

计量

全新药物设计方法与常用软件及其在抗癌药物设计中的应用

doi: 10.3969/j.issn.1006-0111.2014.01.003

南华大学药物药理研究所, 湖南衡阳 421001

English Abstract

Applications of the common software and methods of denovo drug design in the antitumor drug design

Institute of Pharmacy and Pharmacology, University of South China, Hunan Hengyang 421001, China

全文HTML

目录

留言板

全新药物设计方法与常用软件及其在抗癌药物设计中的应用

doi: 10.3969/j.issn.1006-0111.2014.01.003

Applications of the common software and methods of denovo drug design in the antitumor drug design

计量

出版历程

全新药物设计方法与常用软件及其在抗癌药物设计中的应用

doi: 10.3969/j.issn.1006-0111.2014.01.003

南华大学药物药理研究所, 湖南 衡阳 421001

English Abstract

Applications of the common software and methods of denovo drug design in the antitumor drug design

Institute of Pharmacy and Pharmacology, University of South China, Hunan Hengyang 421001, China

全文HTML

目录

南华大学药物药理研究所, 湖南衡阳 421001